Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers

Cancer Science

Volumn 104, Issue 4, 2013, Pages 495-501

  Kondo, Naoya ^a   Temma, Takashi ^a   Shimizu, Yoichi ^a   Watanabe, Hiroyuki ^a   Higano, Keiichi ^b   Takagi, Yoko ^b   Ono, Masahiro ^a   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Kyoto Electronics Manufacturing Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INDIUM 111; INTERSTITIAL COLLAGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN STRUCTURE; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INDIUM RADIOISOTOPES; MATRIX METALLOPROTEINASE 14; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875593086     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12102     Document Type: Article

References (30)

1. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol 2005; 17: 559-64.
2. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-33.
3. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999; 189: 161-8.
4. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446-51.
5. Knäuper V, Will H, López-Otin C et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271: 17124-31.
6. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006; 206: 1-8.
7. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207-14.
8. Crispi S, Calogero RA, Santini M et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS ONE 2009; 4: e7016.
9. Temma T, Sano K, Kuge Y et al. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull 2009; 32: 1272-7.
10. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-36.
11. Sundaresan G, Yazaki PJ, Shively JE et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44: 1962-9.
12. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
13. D'Alessio S, Ferrari G, Cinnante K et al. Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem 2008; 283: 87-99.
14. Remacle AG, Golubkov VS, Shiryaev SA et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012; 72: 2339-49.
15. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000; 11: 2387-401.
16. Toth M, Hernandez-Barrantes S, Osenkowski P et al. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J Biol Chem 2002; 277: 26340-50.
17. Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell 2006; 17: 5390-9.
18. Mori H, Tomari T, Koshikawa N et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002; 21: 3949-59.
19. Atkinson JM, Falconer RA, Edwards DR et al. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res 2010; 70: 6902-12.
20. Shimizu Y, Temma T, Sano K, Ono M, Saji H. Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection. Cancer Sci 2011; 102: 1897-903.
21. Zhu L, Wang H, Wang L et al. High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release 2011; 150: 248-55.
22. Zhu L, Zhang F, Ma Y et al. In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity. Mol Pharm 2011; 8: 2331-8.
23. Van Steenkiste M, Oltenfreiter R, Frankenne F et al. Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent. Cancer Biother Radiopharm 2010; 25: 511-20.
24. Sano K, Temma T, Kuge Y et al. Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method. Biol Pharm Bull 2010; 33: 1589-95.
25. Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol 2007; 96: 46-53.
26. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21: 2153-63.
27. Uehara T, Koike M, Nakata H et al. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. Bioconjug Chem 2007; 18: 190-8.
28. Adams GP, Schier R, McCall AM et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-12.
29. Li L, Yazaki PJ, Anderson AL et al. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem 2006; 17: 68-76.
30. Lub-de Hooge MN, Kosterink JG, Perik PJ et al. Preclinical characterization of 111In-DTPA-Trastuzumab. Br J Pharmacol 2004; 143: 99-106.